Canada’s Drug Agency | Drugs, Health Technologies and Systems.

blinatumomab and dasatinib

Details

Files
Generic Name:
blinatumomab and dasatinib
Project Status:
Pending
Therapeutic Area:
Philadelphia chromosome-positive acute lymphoblastic leukemia
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0384-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​In combination with dasatinib (a tyrosine kinase inhibitor) for the 1st line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Files

Proposed Scope View PDF
Last Updated : July 16, 2025